The global Radionuclide Drug Conjugate(RDC) market was valued at US$ 10740 million in 2025 and is anticipated to reach US$ 20220 million by 2032, at a CAGR of 9.6% from 2026 to 2032.

Radionuclide Drug Conjugate(RDC) Market

Radionuclide-conjugated drugs (RCDs) are a novel type of therapeutic drug combining precise targeting and potent killing. Their structure is similar to antibody-drug conjugates (ADCs), but the toxic payload is replaced by a radionuclide. They mainly consist of four parts: a targeting ligand responsible for specific tumor recognition, a linker arm, a chelating agent to stabilize the bound radionuclide, and the radionuclide itself. After entering the body, the ligand guides the radionuclide to precisely accumulate at the tumor site. The radiation released during radionuclide decay destroys tumor cell DNA from within, achieving highly effective treatment. If imaging radionuclides are used, they can be used for tumor localization and diagnosis.

The market prospects for RCDs are extremely broad, leading to the rapid rise of the radiopharmaceutical industry. The core drivers of future growth lie in technological iteration and application expansion: therapeutic radionuclides are upgrading from current β-radionuclides to next-generation α-radionuclides with stronger and more precise killing power; indications are expanding from prostate cancer and neuroendocrine tumors to more solid tumors and even non-tumor fields. With policy support and capital investment, pharmaceutical companies from various countries are vying to break through bottlenecks in the industrial chain, such as isotope supply, production and distribution. The unique advantages of integrated diagnosis and treatment will make RDC an important pillar for precision cancer treatment.

This report delivers a comprehensive overview of the global Radionuclide Drug Conjugate(RDC) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radionuclide Drug Conjugate(RDC). The Radionuclide Drug Conjugate(RDC) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Radionuclide Drug Conjugate(RDC) market comprehensively. Regional market sizes by Target Ligand Types, by Application, by Medical Uses, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Radionuclide Drug Conjugate(RDC) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Target Ligand Types, by Application, and by region.

Market Segmentation

Scope of Radionuclide Drug Conjugate(RDC) Market Report

Report Metric	Details
Report Name	Radionuclide Drug Conjugate(RDC) Market
Accounted market size in 2025	US$ 10740 million
Forecasted market size in 2032	US$ 20220 million
CAGR	9.6%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Target Ligand Types	Antibody-Drug Conjugates (ARC) Peptide-Drug Conjugates (PRC) Small Molecule-Drug Conjugates (SMRC)
Segment by Medical Uses	Diagnostic RDCs Therapeutic RDCs
Segment by Therapeutic Radionuclide Properties	β-Nuclear Therapy α-Nuclear Therapy
Segment by Application	Prostate Cancer Neuroendocrine Tumors Liver Cancer Kidney Cancer Bone Metastases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Bayer, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Johnson & Johnson, Grand Pharmaceutical Group, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Hengrui Medicine, Xiantong Pharmaceutical, Bivision, SmartNuclide, Full-Life Technologies, Hexin (Suzhou) Pharmaceutical Technology Co., Ltd., Nuoyu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Target Ligand Types, by Application, by Medical Uses, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Radionuclide Drug Conjugate(RDC) companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Target Ligand Types, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Radionuclide Drug Conjugate(RDC) Market growing?

Ans: The Radionuclide Drug Conjugate(RDC) Market witnessing a CAGR of 9.6% during the forecast period 2026-2032.

What is the Radionuclide Drug Conjugate(RDC) Market size in 2032?

Ans: The Radionuclide Drug Conjugate(RDC) Market size in 2032 will be US$ 20220 million.

Who are the main players in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The main players in the Radionuclide Drug Conjugate(RDC) Market are Novartis, Bayer, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Johnson & Johnson, Grand Pharmaceutical Group, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Hengrui Medicine, Xiantong Pharmaceutical, Bivision, SmartNuclide, Full-Life Technologies, Hexin (Suzhou) Pharmaceutical Technology Co., Ltd., Nuoyu Pharmaceutical

What are the Application segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The Applications covered in the Radionuclide Drug Conjugate(RDC) Market report are Prostate Cancer, Neuroendocrine Tumors, Liver Cancer, Kidney Cancer, Bone Metastases, Others

What are the Type segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The Types covered in the Radionuclide Drug Conjugate(RDC) Market report are Antibody-Drug Conjugates (ARC), Peptide-Drug Conjugates (PRC), Small Molecule-Drug Conjugates (SMRC)

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Target Ligand Types

1.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Target Ligand Types: 2021 vs 2025 vs 2032

1.2.2 Antibody-Drug Conjugates (ARC)

1.2.3 Peptide-Drug Conjugates (PRC)

1.2.4 Small Molecule-Drug Conjugates (SMRC)

1.3 Market by Medical Uses

1.3.1 Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Medical Uses: 2021 vs 2025 vs 2032

1.3.2 Diagnostic RDCs

1.3.3 Therapeutic RDCs

1.4 Market by Therapeutic Radionuclide Properties

1.4.1 Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Therapeutic Radionuclide Properties: 2021 vs 2025 vs 2032

1.4.2 β-Nuclear Therapy

1.4.3 α-Nuclear Therapy

1.5 Market by Application

1.5.1 Global Radionuclide Drug Conjugate(RDC) Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Prostate Cancer

1.5.3 Neuroendocrine Tumors

1.5.4 Liver Cancer

1.5.5 Kidney Cancer

1.5.6 Bone Metastases

1.5.7 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Radionuclide Drug Conjugate(RDC) Market Perspective (2021–2032)

2.2 Global Radionuclide Drug Conjugate(RDC) Growth Trends by Region

2.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Radionuclide Drug Conjugate(RDC) Historic Market Size by Region (2021–2026)

2.2.3 Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Region (2027–2032)

2.3 Radionuclide Drug Conjugate(RDC) Market Dynamics

2.3.1 Radionuclide Drug Conjugate(RDC) Industry Trends

2.3.2 Radionuclide Drug Conjugate(RDC) Market Drivers

2.3.3 Radionuclide Drug Conjugate(RDC) Market Challenges

2.3.4 Radionuclide Drug Conjugate(RDC) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Radionuclide Drug Conjugate(RDC) Players by Revenue

3.1.1 Global Top Radionuclide Drug Conjugate(RDC) Players by Revenue (2021–2026)

3.1.2 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Players (2021–2026)

3.2 Global Top Radionuclide Drug Conjugate(RDC) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Radionuclide Drug Conjugate(RDC) Revenue

3.4 Global Radionuclide Drug Conjugate(RDC) Market Concentration Ratio

3.4.1 Global Radionuclide Drug Conjugate(RDC) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugate(RDC) Revenue in 2025

3.5 Global Key Players of Radionuclide Drug Conjugate(RDC) Head Offices and Areas Served

3.6 Global Key Players of Radionuclide Drug Conjugate(RDC), Products and Applications

3.7 Global Key Players of Radionuclide Drug Conjugate(RDC), Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Radionuclide Drug Conjugate(RDC) Breakdown Data by Target Ligand Types

4.1 Global Radionuclide Drug Conjugate(RDC) Historic Market Size by Target Ligand Types (2021–2026)

4.2 Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Target Ligand Types (2027–2032)

5 Radionuclide Drug Conjugate(RDC) Breakdown Data by Application

5.1 Global Radionuclide Drug Conjugate(RDC) Historic Market Size by Application (2021–2026)

5.2 Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Radionuclide Drug Conjugate(RDC) Market Size (2021–2032)

6.2 North America Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021–2026)

6.4 North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Radionuclide Drug Conjugate(RDC) Market Size (2021–2032)

7.2 Europe Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021–2026)

7.4 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size (2021–2032)

8.2 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Region (2021–2026)

8.4 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Radionuclide Drug Conjugate(RDC) Market Size (2021–2032)

9.2 Latin America Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021–2026)

9.4 Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size (2021–2032)

10.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2021–2026)

10.4 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Radionuclide Drug Conjugate(RDC) Introduction

11.1.4 Novartis Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.1.5 Novartis Recent Development

11.2 Bayer

11.2.1 Bayer Company Details

11.2.2 Bayer Business Overview

11.2.3 Bayer Radionuclide Drug Conjugate(RDC) Introduction

11.2.4 Bayer Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.2.5 Bayer Recent Development

11.3 AstraZeneca

11.3.1 AstraZeneca Company Details

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Radionuclide Drug Conjugate(RDC) Introduction

11.3.4 AstraZeneca Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.3.5 AstraZeneca Recent Development

11.4 Eli Lilly

11.4.1 Eli Lilly Company Details

11.4.2 Eli Lilly Business Overview

11.4.3 Eli Lilly Radionuclide Drug Conjugate(RDC) Introduction

11.4.4 Eli Lilly Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.4.5 Eli Lilly Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Details

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Radionuclide Drug Conjugate(RDC) Introduction

11.5.4 Bristol-Myers Squibb Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 Johnson & Johnson

11.6.1 Johnson & Johnson Company Details

11.6.2 Johnson & Johnson Business Overview

11.6.3 Johnson & Johnson Radionuclide Drug Conjugate(RDC) Introduction

11.6.4 Johnson & Johnson Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.6.5 Johnson & Johnson Recent Development

11.7 Grand Pharmaceutical Group

11.7.1 Grand Pharmaceutical Group Company Details

11.7.2 Grand Pharmaceutical Group Business Overview

11.7.3 Grand Pharmaceutical Group Radionuclide Drug Conjugate(RDC) Introduction

11.7.4 Grand Pharmaceutical Group Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.7.5 Grand Pharmaceutical Group Recent Development

11.8 China Isotope & Radiation Corporation

11.8.1 China Isotope & Radiation Corporation Company Details

11.8.2 China Isotope & Radiation Corporation Business Overview

11.8.3 China Isotope & Radiation Corporation Radionuclide Drug Conjugate(RDC) Introduction

11.8.4 China Isotope & Radiation Corporation Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.8.5 China Isotope & Radiation Corporation Recent Development

11.9 Dongcheng Pharmaceutical

11.9.1 Dongcheng Pharmaceutical Company Details

11.9.2 Dongcheng Pharmaceutical Business Overview

11.9.3 Dongcheng Pharmaceutical Radionuclide Drug Conjugate(RDC) Introduction

11.9.4 Dongcheng Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.9.5 Dongcheng Pharmaceutical Recent Development

11.10 Hengrui Medicine

11.10.1 Hengrui Medicine Company Details

11.10.2 Hengrui Medicine Business Overview

11.10.3 Hengrui Medicine Radionuclide Drug Conjugate(RDC) Introduction

11.10.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.10.5 Hengrui Medicine Recent Development

11.11 Xiantong Pharmaceutical

11.11.1 Xiantong Pharmaceutical Company Details

11.11.2 Xiantong Pharmaceutical Business Overview

11.11.3 Xiantong Pharmaceutical Radionuclide Drug Conjugate(RDC) Introduction

11.11.4 Xiantong Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.11.5 Xiantong Pharmaceutical Recent Development

11.12 Bivision

11.12.1 Bivision Company Details

11.12.2 Bivision Business Overview

11.12.3 Bivision Radionuclide Drug Conjugate(RDC) Introduction

11.12.4 Bivision Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.12.5 Bivision Recent Development

11.13 SmartNuclide

11.13.1 SmartNuclide Company Details

11.13.2 SmartNuclide Business Overview

11.13.3 SmartNuclide Radionuclide Drug Conjugate(RDC) Introduction

11.13.4 SmartNuclide Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.13.5 SmartNuclide Recent Development

11.14 Full-Life Technologies

11.14.1 Full-Life Technologies Company Details

11.14.2 Full-Life Technologies Business Overview

11.14.3 Full-Life Technologies Radionuclide Drug Conjugate(RDC) Introduction

11.14.4 Full-Life Technologies Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.14.5 Full-Life Technologies Recent Development

11.15 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

11.15.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details

11.15.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview

11.15.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugate(RDC) Introduction

11.15.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.15.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development

11.16 Nuoyu Pharmaceutical

11.16.1 Nuoyu Pharmaceutical Company Details

11.16.2 Nuoyu Pharmaceutical Business Overview

11.16.3 Nuoyu Pharmaceutical Radionuclide Drug Conjugate(RDC) Introduction

11.16.4 Nuoyu Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

11.16.5 Nuoyu Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Grand Pharmaceutical Group

China Isotope & Radiation Corporation

Dongcheng Pharmaceutical

Hengrui Medicine

Bivision

SmartNuclide

Full-Life Technologies

Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

Nuoyu Pharmaceutical

Xiantong Pharmaceutical

List of Tables

Table 1. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Target Ligand Types (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Antibody-Drug Conjugates (ARC)

Table 3. Key Players of Peptide-Drug Conjugates (PRC)

Table 4. Key Players of Small Molecule-Drug Conjugates (SMRC)

Table 5. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Medical Uses (US$ Million): 2021 vs 2025 vs 2032

Table 6. Key Players of Diagnostic RDCs

Table 7. Key Players of Therapeutic RDCs

Table 8. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Therapeutic Radionuclide Properties (US$ Million): 2021 vs 2025 vs 2032

Table 9. Key Players of β-Nuclear Therapy

Table 10. Key Players of α-Nuclear Therapy

Table 11. Global Radionuclide Drug Conjugate(RDC) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 12. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 13. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (US$ Million), 2021–2026

Table 14. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2021–2026)

Table 15. Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Region (US$ Million), 2027–2032

Table 16. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2027–2032)

Table 17. Radionuclide Drug Conjugate(RDC) Market Trends

Table 18. Radionuclide Drug Conjugate(RDC) Market Drivers

Table 19. Radionuclide Drug Conjugate(RDC) Market Challenges

Table 20. Radionuclide Drug Conjugate(RDC) Market Restraints

Table 21. Global Radionuclide Drug Conjugate(RDC) Revenue by Players (US$ Million), 2021–2026

Table 22. Global Radionuclide Drug Conjugate(RDC) Market Share by Players (2021–2026)

Table 23. Global Top Radionuclide Drug Conjugate(RDC) Players by Tier (Tier 1, Tier 2, and Tier 3), based on Radionuclide Drug Conjugate(RDC) Revenue, 2025

Table 24. Ranking of Global Top Radionuclide Drug Conjugate(RDC) Companies by Revenue (US$ Million) in 2025

Table 25. Global 5 Largest Players Market Share by Radionuclide Drug Conjugate(RDC) Revenue (CR5 and HHI), 2021–2026

Table 26. Global Key Players of Radionuclide Drug Conjugate(RDC), Headquarters and Area Served

Table 27. Global Key Players of Radionuclide Drug Conjugate(RDC), Products and Applications

Table 28. Global Key Players of Radionuclide Drug Conjugate(RDC), Date of General Availability (GA)

Table 29. Mergers and Acquisitions, Expansion Plans

Table 30. Global Radionuclide Drug Conjugate(RDC) Market Size by Target Ligand Types (US$ Million), 2021–2026

Table 31. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Target Ligand Types (2021–2026)

Table 32. Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Target Ligand Types (US$ Million), 2027–2032

Table 33. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Target Ligand Types (2027–2032)

Table 34. Global Radionuclide Drug Conjugate(RDC) Market Size by Application (US$ Million), 2021–2026

Table 35. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2021–2026)

Table 36. Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Application (US$ Million), 2027–2032

Table 37. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2027–2032)

Table 38. North America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 39. North America Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2021–2026

Table 40. North America Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2027–2032

Table 41. Europe Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2021–2026

Table 43. Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2027–2032

Table 44. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 45. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Region (US$ Million), 2021–2026

Table 46. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Region (US$ Million), 2027–2032

Table 47. Latin America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 48. Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2021–2026

Table 49. Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2027–2032

Table 50. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 51. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2021–2026

Table 52. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (US$ Million), 2027–2032

Table 53. Novartis Company Details

Table 54. Novartis Business Overview

Table 55. Novartis Radionuclide Drug Conjugate(RDC) Product

Table 56. Novartis Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 57. Novartis Recent Development

Table 58. Bayer Company Details

Table 59. Bayer Business Overview

Table 60. Bayer Radionuclide Drug Conjugate(RDC) Product

Table 61. Bayer Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 62. Bayer Recent Development

Table 63. AstraZeneca Company Details

Table 64. AstraZeneca Business Overview

Table 65. AstraZeneca Radionuclide Drug Conjugate(RDC) Product

Table 66. AstraZeneca Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 67. AstraZeneca Recent Development

Table 68. Eli Lilly Company Details

Table 69. Eli Lilly Business Overview

Table 70. Eli Lilly Radionuclide Drug Conjugate(RDC) Product

Table 71. Eli Lilly Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 72. Eli Lilly Recent Development

Table 73. Bristol-Myers Squibb Company Details

Table 74. Bristol-Myers Squibb Business Overview

Table 75. Bristol-Myers Squibb Radionuclide Drug Conjugate(RDC) Product

Table 76. Bristol-Myers Squibb Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 77. Bristol-Myers Squibb Recent Development

Table 78. Johnson & Johnson Company Details

Table 79. Johnson & Johnson Business Overview

Table 80. Johnson & Johnson Radionuclide Drug Conjugate(RDC) Product

Table 81. Johnson & Johnson Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 82. Johnson & Johnson Recent Development

Table 83. Grand Pharmaceutical Group Company Details

Table 84. Grand Pharmaceutical Group Business Overview

Table 85. Grand Pharmaceutical Group Radionuclide Drug Conjugate(RDC) Product

Table 86. Grand Pharmaceutical Group Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 87. Grand Pharmaceutical Group Recent Development

Table 88. China Isotope & Radiation Corporation Company Details

Table 89. China Isotope & Radiation Corporation Business Overview

Table 90. China Isotope & Radiation Corporation Radionuclide Drug Conjugate(RDC) Product

Table 91. China Isotope & Radiation Corporation Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 92. China Isotope & Radiation Corporation Recent Development

Table 93. Dongcheng Pharmaceutical Company Details

Table 94. Dongcheng Pharmaceutical Business Overview

Table 95. Dongcheng Pharmaceutical Radionuclide Drug Conjugate(RDC) Product

Table 96. Dongcheng Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 97. Dongcheng Pharmaceutical Recent Development

Table 98. Hengrui Medicine Company Details

Table 99. Hengrui Medicine Business Overview

Table 100. Hengrui Medicine Radionuclide Drug Conjugate(RDC) Product

Table 101. Hengrui Medicine Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 102. Hengrui Medicine Recent Development

Table 103. Xiantong Pharmaceutical Company Details

Table 104. Xiantong Pharmaceutical Business Overview

Table 105. Xiantong Pharmaceutical Radionuclide Drug Conjugate(RDC) Product

Table 106. Xiantong Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 107. Xiantong Pharmaceutical Recent Development

Table 108. Bivision Company Details

Table 109. Bivision Business Overview

Table 110. Bivision Radionuclide Drug Conjugate(RDC) Product

Table 111. Bivision Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 112. Bivision Recent Development

Table 113. SmartNuclide Company Details

Table 114. SmartNuclide Business Overview

Table 115. SmartNuclide Radionuclide Drug Conjugate(RDC) Product

Table 116. SmartNuclide Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 117. SmartNuclide Recent Development

Table 118. Full-Life Technologies Company Details

Table 119. Full-Life Technologies Business Overview

Table 120. Full-Life Technologies Radionuclide Drug Conjugate(RDC) Product

Table 121. Full-Life Technologies Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 122. Full-Life Technologies Recent Development

Table 123. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details

Table 124. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview

Table 125. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugate(RDC) Product

Table 126. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 127. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development

Table 128. Nuoyu Pharmaceutical Company Details

Table 129. Nuoyu Pharmaceutical Business Overview

Table 130. Nuoyu Pharmaceutical Radionuclide Drug Conjugate(RDC) Product

Table 131. Nuoyu Pharmaceutical Revenue in Radionuclide Drug Conjugate(RDC) Business (US$ Million), 2021–2026

Table 132. Nuoyu Pharmaceutical Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Radionuclide Drug Conjugate(RDC) Picture

Figure 2. Global Radionuclide Drug Conjugate(RDC) Market Size Comparison by Target Ligand Types (US$ Million), 2021–2032

Figure 3. Global Radionuclide Drug Conjugate(RDC) Market Share by Target Ligand Types: 2025 vs 2032

Figure 4. Antibody-Drug Conjugates (ARC) Features

Figure 5. Peptide-Drug Conjugates (PRC) Features

Figure 6. Small Molecule-Drug Conjugates (SMRC) Features

Figure 7. Global Radionuclide Drug Conjugate(RDC) Market Size Comparison by Medical Uses (US$ Million), 2021–2032

Figure 8. Diagnostic RDCs Features

Figure 9. Therapeutic RDCs Features

Figure 10. Global Radionuclide Drug Conjugate(RDC) Market Size Comparison by Therapeutic Radionuclide Properties (US$ Million), 2021–2032

Figure 11. β-Nuclear Therapy Features

Figure 12. α-Nuclear Therapy Features

Figure 13. Global Radionuclide Drug Conjugate(RDC) Market Size by Application (US$ Million), 2021–2032

Figure 14. Global Radionuclide Drug Conjugate(RDC) Market Share by Application: 2025 vs 2032

Figure 15. Prostate Cancer Case Studies

Figure 16. Neuroendocrine Tumors Case Studies

Figure 17. Liver Cancer Case Studies

Figure 18. Kidney Cancer Case Studies

Figure 19. Bone Metastases Case Studies

Figure 20. Others Case Studies

Figure 21. Radionuclide Drug Conjugate(RDC) Report Years Considered

Figure 22. Global Radionuclide Drug Conjugate(RDC) Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 23. Global Radionuclide Drug Conjugate(RDC) Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 24. Global Radionuclide Drug Conjugate(RDC) Market Share by Region: 2025 vs 2032

Figure 25. Global Radionuclide Drug Conjugate(RDC) Market Share by Players in 2025

Figure 26. Global Radionuclide Drug Conjugate(RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 27. The Top 10 and 5 Players Market Share by Radionuclide Drug Conjugate(RDC) Revenue in 2025

Figure 28. North America Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. North America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021–2032)

Figure 30. United States Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Canada Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Europe Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Europe Radionuclide Drug Conjugate(RDC) Market Share by Country (2021–2032)

Figure 34. Germany Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. France Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. U.K. Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Italy Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Russia Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Ireland Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Share by Region (2021–2032)

Figure 42. China Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Japan Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. South Korea Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Southeast Asia Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. India Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Australia & New Zealand Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Latin America Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Latin America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021–2032)

Figure 50. Mexico Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Brazil Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Share by Country (2021–2032)

Figure 54. Israel Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Saudi Arabia Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. UAE Radionuclide Drug Conjugate(RDC) Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Novartis Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 58. Bayer Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 59. AstraZeneca Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 60. Eli Lilly Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 62. Johnson & Johnson Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 63. Grand Pharmaceutical Group Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 64. China Isotope & Radiation Corporation Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 65. Dongcheng Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 66. Hengrui Medicine Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 67. Xiantong Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 68. Bivision Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 69. SmartNuclide Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 70. Full-Life Technologies Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 71. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 72. Nuoyu Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugate(RDC) Business (2021–2026)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions